{"entity":{"id":"nct04524871","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li","aka":["Morpheus-Liver"],"tldr":"A phase 1/2 trial of Atezolizumab, Bevacizumab, Tiragolumab in hepatocellular carcinoma, run by Hoffmann-La Roche, active and no longer recruiting.","summary":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) is a phase 1/2 interventional study registered as NCT04524871 by Hoffmann-La Roche, with 518 participants planned, started 2020-11-01 and due to reach its primary completion in 2027-07-30. Interventions recorded: Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Tocilizumab, TPST-1120. Conditions listed: Advanced Liver Cancers. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04524871","url":"https://clinicaltrials.gov/study/NCT04524871"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc","hcc-advanced"],"sections":[],"technologies":[],"targets":[],"drugs":["atezolizumab","bevacizumab","tiragolumab","tocilizumab","adg126"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04524871","phase":"1/2","setting":"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","sponsor":"Hoffmann-La Roche","participation":[{"nct":"NCT04524871","source":"https://clinicaltrials.gov/study/NCT04524871","fetchedAt":"2026-10-07T16:53:21.850Z","studySha256":"adf41e3893fce63f9484c1475f2d1b44d2e68bce325e27e5e4fc65e0b8fc4743","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-03","leadSponsor":"Hoffmann-La Roche","collaboratorCount":4,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":518,"enrolmentType":"ESTIMATED","siteCount":32,"recruitingSiteCount":0,"countries":["China","France","Israel","New Zealand","South Korea","Taiwan","United States"]}],"started":"2020-11-01","startedType":"actual","enrolled":518,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04524871/","neighbours":{"cancer":[{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"adg126","kind":"drug","name":"ADG126","route":"/drugs/adg126/"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"tiragolumab","kind":"drug","name":"Tiragolumab","route":"/drugs/tiragolumab/"},{"id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}]}}